Boston Scientific promotes Joe Fitzgerald to COO; creates three segments Jan 1, 2027

BOSTON SCIENTIFIC CORP

Joseph M. Fitzgerald, 63, EVP and Group President, Cardiovascular, promoted to EVP and COO effective Jan 1, 2027; base salary $1,050,000 and 2027 equity award of $7,000,000.
Three reportable segments created effective Jan 1, 2027: Interventional Therapies (Lance Bates), Rhythm Solutions (Nick Spadea-Anello), MedSurg (Stephen Morse), each reporting to Fitzgerald.
Interventional Therapies segment will include the Penumbra business following the anticipated close of that acquisition.
Mark Bickel, 49, named SVP, Global Accounting Controller and Chief Accounting Officer effective March 1, 2027; Emily Woodworth moves to SVP, Global Finance Controller.
CEO Mike Mahoney said the new operating model will create greater capacity to focus on long-term growth priorities and let businesses move faster.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Joe Fitzgerald

Executive Vice President and Chief Operating Officer

BSX · BOSTON SCIENTIFIC CORP

Effective: 2027-01-01
Filed: October 7, 2026, 6:11 AM ET

On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.97

Joe Fitzgerald changed role as Executive Vice President and Chief Operating Officer at BOSTON SCIENTIFIC CORP.

Action: promoted
Role: Executive Vice President and Chief Operating Officer

Exact text from the filing

On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027.

View on SEC.gov

BOSTON SCIENTIFIC CORP filing history →

Source: SEC EDGAR

accession 0000885725-26-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.